Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P. Neri A, et al. Among authors: musto p. Expert Rev Hematol. 2016 Nov;9(11):1063-1073. doi: 10.1080/17474086.2016.1244002. Epub 2016 Oct 24. Expert Rev Hematol. 2016. PMID: 27759436 Review.
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A; GISMM Cooperative Group; GISL Cooperative Group; GIMEMA Cooperative Group. Musto P, et al. Cancer. 2007 Jun 1;109(11):2285-90. doi: 10.1002/cncr.22700. Cancer. 2007. PMID: 17469169 Free article.
Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S, Boccadoro M, Palumbo A; Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. Musto P, et al. Expert Rev Anticancer Ther. 2008 Oct;8(10):1569-80. doi: 10.1586/14737140.8.10.1569. Expert Rev Anticancer Ther. 2008. PMID: 18925849 Review.
Advanced mast cell disease: an Italian Hematological Multicenter experience.
Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P. Pagano L, et al. Among authors: musto p. Int J Hematol. 2008 Dec;88(5):483-488. doi: 10.1007/s12185-008-0166-4. Epub 2008 Nov 26. Int J Hematol. 2008. PMID: 19034614
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L. Rossi F, et al. Among authors: musto p. Clin Cancer Res. 2009 Jul 1;15(13):4439-45. doi: 10.1158/1078-0432.CCR-08-3150. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509142
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.
Musto P, D'Auria F, Pietrantuono G, Baldini L, Bringhen S, Caravita T, Di Raimondo F, Morabito F, Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A. Musto P, et al. Curr Drug Targets. 2009 Oct;10(10):906-22. doi: 10.2174/138945009789577936. Curr Drug Targets. 2009. PMID: 19663768 Review.
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience.
Molica S, Di Raimondo F, Cutrona G, Fabris S, Mauro F, Brugiatelli M, Baldini L, Musto P, Sacchi S, Cortelezzi A, Foà R, Neri A, Federico M, Ferrarini M, Morabito F; Gruppo Italiano Studio Linfomi (GISL). Molica S, et al. Among authors: musto p. Leuk Res. 2010 Aug;34(8):e217-8. doi: 10.1016/j.leukres.2010.03.014. Epub 2010 Mar 31. Leuk Res. 2010. PMID: 20359746 No abstract available.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: musto p. J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12. J Clin Oncol. 2010. PMID: 20940200 Clinical Trial.
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori). Pagano L, et al. Among authors: musto p. Ann Oncol. 2011 Jul;22(7):1628-1635. doi: 10.1093/annonc/mdq646. Epub 2011 Jan 20. Ann Oncol. 2011. PMID: 21252060 Free article.
Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omede' P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A. Musto P, et al. Crit Rev Oncol Hematol. 2012 May;82(2):141-9. doi: 10.1016/j.critrevonc.2011.04.005. Epub 2011 Jun 29. Crit Rev Oncol Hematol. 2012. PMID: 21719304
624 results